Argan (AGX) is up 6.3% today. Here is some analysis on what might have caused this price movement.
Analysis: The move appears tied to continued momentum in power-infrastructure contractors, as investor enthusiasm around data-center-driven electricity demand has been lifting the group. With Argan’s recent large EPC notices-to-proceed and visibility disclosures still fresh, buyers may be extrapolating stronger multi-quarter fundamentals, even without a same-day company-specific headline.
Details:
Sources:
SEC.gov, Business Wire, Trefis, MarketBeat
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$AGX Insider Trading Activity
$AGX insiders have traded $AGX stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.
Here’s a breakdown of recent trading of $AGX stock by insiders over the last 6 months:
- CYNTHIA FLANDERS has made 0 purchases and 2 sales selling 34,000 shares for an estimated $11,426,700.
- WILLIAM F. LEIMKUHLER has made 0 purchases and 6 sales selling 29,422 shares for an estimated $9,536,020.
- CHARLES EDWIN IV COLLINS (CHIEF EXECUTIVE OFFICER, GEMMA) has made 0 purchases and 4 sales selling 32,500 shares for an estimated $9,280,025.
- JAMES W QUINN has made 0 purchases and 4 sales selling 31,001 shares for an estimated $8,256,565.
- PETER W GETSINGER has made 0 purchases and 6 sales selling 22,697 shares for an estimated $6,767,616.
- JOHN RONALD JR. JEFFREY has made 0 purchases and 3 sales selling 12,398 shares for an estimated $4,093,402.
- DAVID HIBBERT WATSON (PRESIDENT AND CEO) has made 0 purchases and 2 sales selling 5,000 shares for an estimated $1,382,400.
- KAREN SWEENEY sold 390 shares for an estimated $103,057
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AGX Hedge Fund Activity
We have seen 197 institutional investors add shares of $AGX stock to their portfolio, and 262 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MAVERICK CAPITAL LTD added 438,858 shares (+inf%) to their portfolio in Q4 2025, for an estimated $137,502,988
- LORD, ABBETT & CO. LLC removed 206,171 shares (-78.4%) from their portfolio in Q4 2025, for an estimated $64,597,497
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 125,534 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $39,332,312
- VALIANT CAPITAL MANAGEMENT, L.P. removed 120,327 shares (-47.3%) from their portfolio in Q4 2025, for an estimated $37,700,855
- KINETIC PARTNERS MANAGEMENT, LP added 117,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $36,658,440
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 107,076 shares (-81.8%) from their portfolio in Q4 2025, for an estimated $33,549,052
- JACOBS LEVY EQUITY MANAGEMENT, INC added 106,757 shares (+69.7%) to their portfolio in Q4 2025, for an estimated $33,449,103
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AGX Analyst Ratings
Wall Street analysts have issued reports on $AGX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- GLJ Research issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for $AGX, check out Quiver Quantitative's $AGX forecast page.
$AGX Price Targets
Multiple analysts have issued price targets for $AGX recently. We have seen 4 analysts offer price targets for $AGX in the last 6 months, with a median target of $347.0.
Here are some recent targets:
- Robert Brown from Lake Street set a target price of $325.0 on 12/05/2025
- Michael Fairbanks from JP Morgan set a target price of $370.0 on 12/01/2025
- Austin Wang from GLJ Research set a target price of $369.0 on 11/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.